Latest News

Birmingham, United Kingdom – A highly aggressive form of leukaemia which is activated by mutations in signalling molecules is maintained by a web of regulatory proteins downstream of these signals. New research published in Cell Reports shows that a complex network of interacting genes activated by this altered signalling may...
As we enter what I consider to be the most wonderful time of the year, I reflect on why this season of giving is so magical. Does it really have anything to do with the gifts under the tree, the parties, or the Christmas lights? Many of us fill our December...
Researchers now believe that ALS, or amyotrophic lateral sclerosis, starts well before its debilitating symptoms appear, a finding that they say could eventually lead to an effective treatment. Protein clumps in cells that show up only after damage has occurred, rather than at the onset of the disease, appear responsible...
Stockholm, Sweden – Blood fat-lowering statins could slow the progression of Alzheimer’s disease, at least for some patients. This is the result of a new study led by Karolinska Institutet published in Alzheimer Research and Therapy. But the researchers are cautious in their interpretations and see the results as a...
KUSA – Beauty is only skin deep. Everyone knows that. But our actions don’t always reflect that understanding. For a clear picture of what that means we turn to the story of a teenager, yes a teenager. Seventeen-year-old Kelley Sperry is surrounded by peers that many of us might view...
Bethesda, MD — The American Gastroenterological Association (AGA) released a new evidence-based guideline recommending the use of blood and stool-based biomarkers to help manage Crohn’s disease, a type of inflammatory bowel disease (IBD). IBD is estimated to affect 2.74 million people in the U.S. The guideline was published today in...
SHANGHAI, China — YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study by YolTech is a single-arm, open-label, dose-escalation clinical...
LARKSPUR, Calif. — Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced dosing of the first patient in the initial Phase 2 expansion cohorts of its Phase 1/2 clinical trial evaluating AU-007 for treatment of unresectable locally advanced or metastatic...